Telomir Pharmaceuticals Secures Global Rights to Telomir-1, Enhancing Market Potential and Value Growth

Telomir Pharmaceuticals has executed a binding LOI to acquire TELI Pharmaceuticals, securing worldwide rights to its lead therapy, Telomir-1. The transaction unifies global IP rights, enabling potential shareholder contributions of up to $5 million. This strengthens Telomir's foundation for partnerships, licensing, and long-term value creation. With worldwide rights, Telomir can pursue global or regional partnerships, out-licensing, or asset-sale opportunities across markets where ex-U.S. demand exceeds U.S. demand.

Telomir Pharmaceuticals (NASDAQ:TELO) has executed a binding Letter of Intent (LOI) to acquire TELI Pharmaceuticals, securing worldwide rights to its lead therapy, Telomir-1. The transaction unifies global IP rights and includes potential shareholder contributions of up to $5 million, strengthening Telomir's foundation for partnerships, licensing, and long-term value creation.

The acquisition aligns Telomir's U.S. rights with TELI's ex-U.S. intellectual property portfolio, covering markets across Europe, Canada, Mexico, China, Japan, South Korea, India, Israel, Australia, Argentina, Uruguay, Taiwan, and the United Arab Emirates. This unified structure positions Telomir to capture the full commercial value of Telomir-1 across oncology, metabolic, and age-related diseases.

Under the LOI, each outstanding share of TELI common stock will be exchanged for shares of TELO common stock, with the exchange ratio determined by an independent valuation. The transaction also includes potential contributions of up to $5 million in cash or cash equivalents from certain TELI shareholders over the duration of the collaboration. These contributions are scheduled as follows: $1 million at closing, $2 million upon IND acceptance, and $2 million upon Phase 1/2 initiation. The transaction is subject to shareholder approval and regulatory conditions.

Erez Aminov, Chief Executive Officer of Telomir, stated, "Executing this binding LOI transforms Telomir-1 from a U.S.-focused asset into a global platform. Strategically, it gives us cleaner access to partnership, licensing, or even asset sale opportunities across continents. Economically, the addressable market outside the United States is larger than inside it. We believe this unified structure positions Telomir for significant long-term value creation as we continue advancing our epigenetic and longevity programs."

Dr. Itzchak Angel, Chief Scientific Advisor of Telomir, added, "This global alignment enables us to plan development for true worldwide impact. It streamlines our path to explore Telomir-1 in oncology, metabolic, and degenerative diseases such as breast and pancreatic cancer, AMD, Progeria, Wilson's disease, and Type 2 diabetes, where our preclinical data already show compelling functional restoration."

Telomir-1 is an investigational oral small-molecule epigenetic therapy designed to reset abnormal DNA methylation patterns, stabilize telomeres, and restore proper gene regulation, addressing the root biological causes of cancer, aging, and degenerative disease. Across multiple preclinical models, Telomir-1 has shown activity at the intersection of epigenetic control, DNA methylation balance, telomere maintenance, metal regulation, and mitochondrial health.

From a commercial perspective, unifying worldwide rights enables Telomir to access multi-hundred-billion-dollar opportunities. Global oncology spending alone is projected to exceed $400 billion by 2028 (IQVIA 2024), while the combined markets for AMD, diabetes, and neurodegenerative diseases surpass $1 trillion annually.

The transaction is subject to shareholder approval, regulatory, and diligence conditions. TELI shareholders face a six-month lockup period.